The Influence of Axial Length on Visual Quality Following SMILE Surgery in Patients with High Myopia
Launched by YUHAO SHAO · Mar 20, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The study enrolled 113 highly myopic patients (202 eyes) who underwent SMILE surgery at Shanghai's Tenth People's Hospital. Patients were classified into three groups based on the axial length before surgery: Group A (AL \< 26 mm, 62 eyes), Group B (26 mm ≤ AL \< 27 mm, 88 eyes), and Group C (AL ≥ 27 mm, 52 eyes). Preoperative and postoperative evaluations included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), equivalent spherical error(SE), and corneal high order aberration. Subjective visual quality was assessed using the Quality of Vision (QoV) quest...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • manifest refraction spherical equivalent refraction exceeding -6.00D;
- • stable myopia for a duration of at least 2 years;
- • corrected distance visual acuity of at least 20/25;
- • annual myopic spherical equivalent increment less than - 0.50 D.
- Exclusion Criteria:
- • a history of moderate to severe dry eye as well as any ocular or systemic disease.
About Yuhao Shao
Yuhao Shao is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodologies and ethical practices, Yuhao Shao leads the design and implementation of clinical trials across various therapeutic areas. The organization emphasizes collaboration with healthcare professionals and regulatory bodies to ensure compliance and the highest standards of safety and efficacy. Through its commitment to transparency and excellence, Yuhao Shao aims to contribute significantly to the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported